Oxelius Vivi-Anne
Department of Pediatrics, University Hospital, Lund University, 221 85, Lund, Sweden.
Immunol Res. 2008;40(2):179-91. doi: 10.1007/s12026-007-0007-1.
The IGHG (ImmunoGlobulin constant Heavy G chain) genes are situated close to the IGHE gene on chromosome 14q32, 5'mu, delta, gamma3, gamma1, alpha1, gamma2, gamma4, epsilon, alpha2, 3', in linkage disequilibrium. The polymorphism of gamma3, gamma1 and gamma2 genes, is investigated as alternative allotypes. They are inherited in a Mendelian fashion and are expressed randomly in allelic exclusion. The alternative and functionally different gamma3, gamma1 and gamma2 gene variants, are found in four IGHG haplotypes, coding 4 B-cell variants: IGHGbfn (=B1-cells), IGHGbf-n (=B2-cells), IGHGgan (=B3-cells) and IGHGga-n (=B4-cells). The dominance of the IGHG2n allele from the IGHGbfn haplotype (=B1-cells) has been shown in repeated investigations, namely in patients with asthma and allergy with increased serum levels of IgE > 600 ku/l and more often so in those with IgE > 1,000 ku/l or IgG4>1 g/l, in childhood asthma patients with mean level of IgE = 1,762 ku/l and in allergen exposed individuals developing laboratory animal allergy. In children with non-atopy and mean IgE level = 9.5 ku/l there is instead a dominance of the alternative allotypes from the IGHGga-n (=B4-cells) with IGHG2-n alleles. In a case-control study allergic children with a family history of allergy, clinically manifest allergy and/or positive SPT, the IGHGbfn haplotype (=B1-cells) with the IGHG2n allele dominates, with increased risk of atopy and the IGHGbf-n haplotype (=B2-cells) with the IGHG2-n allele is infrequent with low risk, probably protective against atopy. The phenotypic expressions of the IGHGbfn haplotype (=B1 cells) and IGHGbfn/bfn diplotypes (B1/B1-cells) are increased IgG2n allotype together with increased IgE serum levels and IgE sensitisation in agreement with atopy. The alternative IGHGga-n/ga-n diplotype (B4/B4-cells) express low IgG1a- and IgG2-n allotypes, together with low IgE and non-IgE sensitisation, in agreement with non-atopy. Together these studies have given us a greater understanding of the involvement of IGHG genes, IGHG coded B-cells and immunochemical and functional variants of IgG molecules describing different forms of asthma and allergy, which will improve diagnoses and treatment.
免疫球蛋白恒定重链G(IGHG)基因位于14号染色体q32上的免疫球蛋白E(IGHE)基因附近,顺序为5'端的μ、δ、γ3、γ1、α1、γ2、γ4、ε、α2及3'端,处于连锁不平衡状态。γ3、γ1和γ2基因的多态性作为替代同种异型进行研究。它们以孟德尔方式遗传,并在等位基因排斥中随机表达。在四种IGHG单倍型中发现了功能不同的γ3、γ1和γ2基因变异体,编码4种B细胞变异体:IGHGbfn(=B1细胞)、IGHGbf - n(=B2细胞)、IGHGgan(=B3细胞)和IGHGga - n(=B4细胞)。多次研究表明,来自IGHGbfn单倍型(=B1细胞)的IGHG2n等位基因具有优势,即在哮喘和过敏患者中,血清IgE水平>600 ku/l时出现,IgE>1000 ku/l或IgG4>1 g/l时更常见;在儿童哮喘患者中,平均IgE水平为1762 ku/l;在接触变应原并发生实验动物过敏的个体中。在非特应性且平均IgE水平 = 9.5 ku/l的儿童中,相反地,来自IGHGga - n(=B4细胞)且带有IGHG2 - n等位基因的替代同种异型占优势。在一项病例对照研究中,有过敏家族史、临床有明显过敏表现和/或皮肤点刺试验阳性的过敏儿童中,带有IGHG2n等位基因的IGHGbfn单倍型(=B1细胞)占优势,特应性风险增加;而带有IGHG2* - n等位基因的IGHGbf - n单倍型(=B2细胞)少见,风险低,可能对特应性有保护作用。IGHGbfn单倍型(=B1细胞)和IGHGbfn/bfn双倍型(B1/B1细胞)的表型表达是IgG2n同种异型增加,同时血清IgE水平和IgE致敏性增加,与特应性一致。替代的IGHGga - n/ga - n双倍型(B4/B4细胞)表达低水平的IgG1a - 和IgG2* - n同种异型,同时IgE和非IgE致敏性低,与非特应性一致。这些研究共同使我们对IGHG基因、IGHG编码的B细胞以及IgG分子的免疫化学和功能变异体在不同形式哮喘和过敏中的作用有了更深入的了解,这将有助于改善诊断和治疗。